HLHui Li

Hui Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hui Li has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Feng Tian

    Department of Gastroenterology, Shengjing Hospital of China Medical University, China

    5 shared publications
  • Feng Tian

    Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, China

    3 shared publications
  • Yajie Zhang

    Department of Gastroenterology, Shengjing Hospital of China Medical University , Shenyang, Liaoning , China

    2 shared publications
  • Ying Xie

    Department of Gastroenterology, Shengjing Hospital of China Medical University

    2 shared publications
  • Yue Li

    Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    2 shared publications
  • Bei Tan

    Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing, P. R. China

    1 shared publication

Latest Publications

  • Open Access

    Diagnostic and therapeutic challenges in colonic eosinophilic abscess complicated with eosinophilic vasculitis: a case report and literature review

    by Na Ding, Jianru Zhao, Feng Tian, Hui Li

    This case report and literature review present a 52-year-old male with a sigmoid eosinophilic abscess (EA) complicated by eosinophilic vasculitis (EoV), resulting in thrombosis and intestinal perforation. The patient presented with acute abdominal pain and melena. Laboratory tests revealed marked eosinophilia, elevated D-dimer levels, and a white blood cell count consistent with systemic inflammation. Contrast-enhanced computed tomography (CECT) identified extensive vascular thrombosis and bowel wall compromise, necessitating surgical intervention. Histopathological examination confirmed the diagnosis of EA with associated eosinophilic infiltration in the intestinal wall. This case highlights the diagnostic and therapeutic challenges of eosinophilic disorders, particularly the need for awareness of their potential complications. It also emphasizes the importance of timely intervention in managing such rare conditions. Through a review of the relevant literature, we further discuss the characteristics, differential diagnosis, and management strategies for EA and EoV.

  • Open Access

    Unraveling the complexity of IgG4-related aortitis and periarteritis: from pathogenesis to clinical practice

    by Yan Wang, Feng Tian, Hui Li

    IgG4-related disease (IgG4-RD) is a chronic fibrotic inflammatory condition characterized by elevated serum IgG4 levels and the infiltration of IgG4-bearing plasma cells in affected organs. It can involve various organs, particularly large vessels. IgG4-related aortitis/periaortitis and periarteritis (IgG4-related PAO/PA) predominantly affect the abdominal aorta and iliac arteries, with a higher prevalence in elderly males. This condition exhibits distinct clinical, histologic, and radiological features compared to IgG4-RD without vascular involvement and other immune-associated vasculitides. IgG4-related PAO/PA diagnosis primarily relies on histopathological findings and imaging studies. Glucocorticoids (GCs) are the mainstay of treatment, often combined with immunosuppressants (IMs), while B- and T-cell-targeted therapies are under investigation. Although most patients respond well to treatment, the disease can be life-threatening due to complications such as myocardial infarction, aortic dissection, and aneurysmal rupture. Therefore, understanding these characteristics is crucial for clinicians to make accurate diagnoses and implement effective treatment strategies. This review provides a comprehensive overview of the current understanding of the pathogenesis, histopathological characteristics, clinical features, diagnosis, treatment, and prognosis of IgG4-related PAO/PA.


  • Open Access

    Upadacitinib for refractory Behçet’s disease with myelodysplastic syndrome and trisomy 8/9: a case report and mechanistic insights

    by Yukai Wang, Feng Tian, Hui Li

    Background: Behçet’s disease (BD), a multisystemic inflammatory disorder with genetic predisposition, is frequently complicated by myelodysplastic syndrome (MDS), particularly in cases harboring trisomy 8. Patients with refractory BD-MDS exhibit poor responses to conventional therapies, including glucocorticoids and TNF-α inhibitors, underscoring the need for novel therapeutic strategies. Janus kinase (JAK) inhibitors, which target cytokine-driven inflammation, represent a promising approach; however, clinical evidence in genetically complex BD-MDS cases remains limited.Case presentation: We report a 29-year-old female with refractory intestinal BD, MDS, and dual trisomy 8/9, who presented with recurrent ulcers, thrombocytopenia, and ileocolonic resection due to perforation. Despite sequential therapies (thalidomide, prednisolone, and infliximab), disease progression persisted. Initiation of upadacitinib (45 mg/day), a selective JAK1 inhibitor, resulted in symptom resolution within one week and complete mucosal healing confirmed by colonoscopy at three months. Dose reduction to 15 mg/day led to disease relapse, while maintenance at 30 mg/day sustained remission over 12 months.Methods: Immunohistochemical (IHC) analysis of intestinal specimens from the patient and three additional BD cases revealed robust phosphorylation of JAK1 and STAT3 in mucosal epithelium, stroma, and inflammatory infiltrates, particularly within occluded submucosal vessels. These findings mechanistically implicate JAK-STAT hyperactivation in BD-associated vascular pathology.Conclusion: This study highlights the efficacy of upadacitinib in managing refractory BD with MDS and dual trisomy 8/9, a genetically complex phenotype. The dose-dependent response underscores the importance of tailored dosing strategies. Our mechanistic data further support JAK inhibition as a viable therapeutic alternative for TNF-α inhibitor-resistant BD. These results warrant validation through randomized controlled trials to optimize therapeutic protocols for similar high-risk populations.


  • Open Access

    Comparison of accelerated and standard infliximab induction regimens in acute severe ulcerative colitis using propensity score analysis: a retrospective multicenter study in China

    by Xinyu Liu, Hui Li, Feng Tian, Ying Xie, Xiaoqi Zhang, Min Zhi, Min Zhang, Xiaomei Song, Hong Guo, Xiaofei Li, et al.

    The optimal regimen of infliximab salvage in acute severe ulcerative colitis (ASUC) patients remains controversial. This study aimed to compare accelerated and standard infliximab induction in Chinese ASUC patients, and to explore risk factors and concrete accelerated regimens for them. Data were retrospectively collected from steroid-refractory ASUC patients receiving infliximab as rescue therapy at seven tertiary centers across China. Outcomes including colectomy and clinical remission (Mayo score ≤ 2 and every subscore ≤ 1 at Day 14) rates were compared between patients receiving accelerated and standard infliximab induction using propensity score adjustment for potential confounders. The dose–response relationship was explored by plotting restricted cubic splines. Logistic regression and Cox proportional hazards regression analyses were performed to determine risk factors for adverse outcomes. A systematic review and meta-analysis was also performed. A total of 76 patients were analysed: 29 received standard and 47 received accelerated induction. The accelerated group had a higher 90-day colectomy rate (17.8% vs 0%, P = 0.019) and lower clinical remission rate (27.7% vs 65.5%, P = 0.001). After adjusting for propensity score and institution, there was no significant difference in colectomy or clinical remission rates (both P > 0.05). Dose–effect curves showed decreased colectomy hazard with higher cumulative infliximab dosage within 5 days, with no improvement observed for increasing cumulative infliximab dosage within 28 days. Multivariate logistic regression analyses revealed C-reactive protein of >10 mg/L at infliximab initiation (odds ratio = 5.00, 95% confidence interval: 1.27–24.34) as an independent risk factor for no clinical remission. Meta-analysis also revealed no significant difference in colectomy rates at 3 months (P = 0.54). After adjusting for confounders, there were no significant differences in colectomy or clinical remission rates between accelerated and standard infliximab induction among ASUC patients. Early administration of an intensified dosage within 5 days may be beneficial. Elevated C-reactive protein at infliximab initiation indicated need for intensive treatment.


  • Solitary Rectal Ulcer Syndrome Coexisting with Colitis Cystica Profunda—Is Mucosal Resection Radical or Not?

    by Yajie Zhang, Feng Tian, Hui Li

    Lay Summary: We highlight the key diagnostic features of solitary rectal ulcer syndrome coexisting with colitis cysticaprofunda in order to increase awareness of the postoperative recurrence of the diseases.


  • Open Access

    Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning

    by Si Yu, Hui Li, Yue Li, Hui Xu, Bei Tan, Bo-Wen Tian, Yi-Min Dai, Feng Tian, Jia-Ming Qian

    Background: The early prediction of intravenous corticosteroid (IVCS) resistance in acute severe ulcerative colitis (ASUC) patients remains an unresolved challenge. This study aims to construct and validate a model that accurately predicts IVCS resistance. Methods: A retrospective cohort was established, with consecutive inclusion of patients who met the diagnosis criteria of ASUC and received IVCS during index hospitalization in Peking Union Medical College Hospital between March 2012 and January 2020. The primary outcome was IVCS resistance. Classification models, including logistic regression and machine learning-based models, were constructed. External validation was conducted in an independent cohort from Shengjing Hospital of China Medical University. Results: A total of 129 patients were included in the derivation cohort. During index hospitalization, 102 (79.1%) patients responded to IVCS and 27 (20.9%) failed; 18 (14.0%) patients underwent colectomy in 3 months; 6 received cyclosporin as rescue therapy, and 2 eventually escalated to colectomy; 5 succeeded with infliximab as rescue therapy. The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and C-reactive protein (CRP) level at Day 3 are independent predictors of IVCS resistance. The areas under the receiver-operating characteristic curves (AUROCs) of the logistic regression, decision tree, random forest, and extreme-gradient boosting models were 0.873 (95% confidence interval [CI], 0.704–1.000), 0.648 (95% CI, 0.463–0.833), 0.650 (95% CI, 0.441–0.859), and 0.604 (95% CI, 0.416–0.792), respectively. The logistic regression model achieved the highest AUROC value of 0.703 (95% CI, 0.473–0.934) in the external validation. Conclusions: In patients with ASUC, UCEIS and CRP levels at Day 3 of IVCS treatment appeared to allow the prompt prediction of likely IVCS resistance. We found no evidence of better performance of machine learning-based models in IVCS resistance prediction in ASUC. A nomogram based on the logistic regression model might aid in the management of ASUC patients.


  • Open Access

    Multisegmental Hypoganglionosis: A Rare Cause of Recurrent Bowel Obstruction and Intestinal Ulcers

    by Hui Li, Hong Shu, Ying Xie, Hong Zhang, Mingming Cui, Yuying Gao, Feng Tian

    To the Editors: Hypoganglionosis (HG) is a rare condition characterized by a reduced number of ganglion cells within the colonic submucosal (Meissner) and myenteric (Auerbach) plexuses. The most common clinical manifestations are chronic constipation or pseudo-obstruction.1 Definitive diagnosis is only possible by full-thickness biopsy; therefore, the condition is difficult to diagnose preoperatively. Herein, we present a rare case of recurrent intestinal obstruction and intestinal ulcers, which was finally diagnosed as multisegmental HG after 3 operations. A 56-year-old Chinese man was admitted to hospital in September 2018 with symptoms of recurrent bowel obstruction for 1 year. Colonoscopy showed ulcers around the hepatic flexure. Computed tomography enterography showed gross dilation of the ascending and transverse colon ( Figure 1A). Right hemicolectomy was performed, and Crohn’s disease was suspected postoperatively. However, constipation recurred immediately. In February 2019, he visited our hospital with intestinal bleeding. Computed tomography enterography showed obvious dilation of...


  • Pulmonary Infection Due to Reactivation of Latent Epstein-Barr Virus in a Patient With Crohn’s Disease Treated With Infliximab

    by Yajie Zhang, Feng Tian, Hui Li

    To the Editors: Patients with inflammatory bowel disease (IBD) are at risk for opportunistic infections due to their immunosuppressed state. Anti-tumor necrosis factor α agents are effective in treating IBD; however, they may possibly facilitate the reactivation of the Epstein-Barr virus (EBV), as tumor necrosis factor α plays an important role in viral clearance.1,2 Here, we present the case of a Chinese teenager with Crohn’s disease (CD) who developed EBV-associated pulmonary infection after infliximab (IFX) was initiated. We believe that the clinical course and radiological manifestations can increase our knowledge about EBV infection–associated pulmonary involvement. A 15-year-old boy was admitted to our department with complaints of intermittent abdominal pain, diarrhea, and weight loss for 6 months. He was diagnosed with CD and administered IFX. However, newly formed round lesions in the lung were observed on chest computed tomography (CT) 2 weeks after the first IFX dose (...


  • Open Access

    Pregnancy in the blind hemi-cavity of Robert's uterus: a case report

    by Yan Liu, Shanshan Wang, Yue Hong, Jia Wang, Junqiao Niu, Xiaojuan Li, Hui Li, Yan Wang


  • Clostridium butyricum Supernatant Regulates the Expression of RORγt in HCT-116 Cells by Inhibiting the TLR2/MyD88/NF-κB Signaling Pathway

    by Ying Xie, Linyan Zhou, Hui Li, Yan Li

    In this study, we treated HCT-116 cells with Clostridium butyricum (C. butyricum) supernatant and observed its effects on the TLR2/MyD88/NF-κB signaling pathway and RORγt, to further explore the possible immune regulatory mechanism of C. butyricum. Our results showed that C. butyricum supernatant downregulated the mRNA and protein levels of TLR2, MyD88, NF-κBp65, and RORγt in HCT-116 cells and the protein levels of phospho-NF-κBp65. Partial blockage of TLR2 by CD282 weakened the inhibitory effects of C. butyricum supernatant on the above pathway components. Those component levels were still inhibited by C. butyricum supernatant after Pam3CSK4 activation of TLR2. In summary, C. butyricum supernatant can inhibit the TLR2/MyD88/NF-κB signaling pathway and the expression of RORγt in HCT-116 cells. These effects are at least partly achieved through inhibition of TLR2.